MCOLN1 and cancer: Subsequent experiments comparing the proliferation of cancer cells bearing wild-type HRAS and oncogenic HRAS mutations revealed an intrinsic vulnerability of oncogenic HRAS-driven cancer cells to genetic depletion or pharmacological inhibition of TRPML1.